Search
InMed Pharmaceuticals Inc
INMAdd to Watchlist
1.560USD
-0.030-1.89%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.17MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.89%
5 Days
+1.30%
1 Month
0.00%
6 Months
+39.29%
Year to Date
+47.17%
1 Year
-46.39%
Key Figures
1.580Open
1.600High
33.20KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
1.00%Turnover Ratio
1.590Prev. Close
1.550Low
31.92KTurnover
LossP/E Static
0.75P/B
0.00%Div Yield TTM
-85.12%ROA
7.98052wk High
1.13Volume Ratio
-8.16MNet Profit
3.31MShares
-2.1210EPS TTM
0.94Beta
-112.65%ROE
0.57552wk Low
3.14%Amplitude
24.79%Gross Margin
5.17MMarket Cap
0.42Reward/Risk
4.62%Risk Rate
TradingKey Stock Score of InMed Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
InMed Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 240 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
InMed Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
InMed Pharmaceuticals Inc Highlights
StrengthsRisks
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.94M.
Undervalued
The company’s latest PE is -0.74, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 320.11K shares, decreasing 12.00% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
InMed Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
InMed Pharmaceuticals Inc Info
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Ticker SymbolINM
CompanyInMed Pharmaceuticals Inc
CEOAdams (Eric A)
Websitehttps://www.inmedpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of InMed Pharmaceuticals Inc (INM)?
The current price of InMed Pharmaceuticals Inc (INM) is 1.56.
What is the symbol of InMed Pharmaceuticals Inc?
The ticker symbol of InMed Pharmaceuticals Inc is INM.
What is the 52-week high of InMed Pharmaceuticals Inc?
The 52-week high of InMed Pharmaceuticals Inc is 7.98.
What is the 52-week low of InMed Pharmaceuticals Inc?
The 52-week low of InMed Pharmaceuticals Inc is 0.57.
What is the market capitalization of InMed Pharmaceuticals Inc?
The market capitalization of InMed Pharmaceuticals Inc is 5.17M.
What is the Earnings Per Share (EPS TTM) of InMed Pharmaceuticals Inc (INM)?
The Earnings Per Share (EPS TTM) of InMed Pharmaceuticals Inc (INM) is -8.36.